Solid tumors metastasizing to the brain are a frequent occurrence with an estimated
incidence of approximately 30% of all cases. The longstanding conventional standard of …

Simple Summary Immunotherapy stands as a cornerstone in the treatment of advanced lung
cancer patients without an oncogenic driver mutation. This comprehensive review provides …

Abstract Introduction In CheckMate 227 Part 1, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with metastatic NSCLC, regardless of tumor …

For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint
blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L) 1 …

Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged
overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or …

Abstract Background In CheckMate 9LA (NCT03215706), first-line nivolumab plus
ipilimumab with chemotherapy (2 cycles) significantly improved overall survival versus …

Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient)
has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an …

The presence of brain metastases (BM) is a negative prognostic factor for patients with
advanced nonsmall cell lung cancer (NSCLC). Their incidence seems to be higher in …

Up to 40% of patients with non-small cell lung cancer (NSCLC) develop central nervous
system (CNS) metastases. Current treatments for this subgroup of patients with advanced …

Background The combination of platinum-based chemotherapy with immune-checkpoint
inhibitors (ICIs) is a standard of care option in the front-line treatment of advanced non-small …